Dash Bio, Inc.

BOSTON, MA · Founded 2024 · CIK 0002041370 · Medtech

Automated bioanalysis platform for high-throughput sample processing and analysis

dash.bio →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$17M
2 Form D · Jun 2025
15 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$6,121,000
Private capital raisedForm D · SEC$10,999,976
Form D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1454DELPOR INC—$1.4M
1455Daedalus Medical Solutions, Inc.—$380K
1456ACES Diagnostics, Inc.—$1.9M
1457Dash Bio, Inc.—$17M
1458CAERUS CORP.—$3.3M
1459ProPedix, Inc.—$800K
1460Thynk, Inc.—$7.7M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • DAVID JOHNSONDirector · Executive Officer
  • ALEXANDER TALLETTDirector · Executive Officer

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.